Innovative Solutions in Science and Technology
Empowering your projects with cutting-edge research and tools.
Sifis Pediaditakis PhD
A highly accomplished neuroscientist with 15+ years of industry and academic experience in drug discovery and translational research, he specializes in translatable complex in vitro models that bridge neurobiology with mechanistic studies in human cell systems to drive therapeutic innovation. He has led multi-functional teams in early-stage project ideation, target validation, screening, and hit-to-lead preclinical programs for small molecules and antibody therapeutics.
Throughout his career, he has held leadership roles at Emulate Inc., Alchemab Therapeutics, and Vesalius Therapeutics, pioneering innovative approaches to developing novel therapeutics for neurodegenerative diseases. At Emulate, he spearheaded the development of the Brain-Chip, advancing the understanding of neuroinflammation and neurodegeneration. At Alchemab, he built and led a research team that integrated cutting-edge human-based models to accelerate drug discovery, with multiple preclinical programs successfully progressing toward clinical testing.
He is currently the Co-founder, Vice President, and Head of Biology at Phragma Therapeutics, where he leads discovery biology efforts focused on developing next-generation therapeutics aimed at restoring barrier function to address neurological disorders.
His expertise extends beyond neurodegeneration, as he also led biology efforts for experiments conducted on the International Space Station (ISS), investigating how space travel affects neuronal function (Granted U.S. Patent). Recognized for his contributions to science, his work has been honored with The Scientist’s Top 10 Innovations of 2021 award for the Human Brain-Chip project, and he was named one of Greek America’s Forty Under 40 in 2022.
